|
|
Volumn 340, Issue 4, 1999, Pages 310-312
|
|
Anticytokine therapy - A new era in the treatment of rheumatoid arthritis?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ETANERCEPT;
FC RECEPTOR;
HYBRID PROTEIN;
INFLIXIMAB;
METHOTREXATE;
TUMOR NECROSIS FACTOR ANTIBODY;
TUMOR NECROSIS FACTOR RECEPTOR;
UNCLASSIFIED DRUG;
CLINICAL TRIAL;
DRUG EFFICACY;
DRUG HALF LIFE;
EDITORIAL;
HUMAN;
IMMUNOPATHOGENESIS;
INTRAVENOUS DRUG ADMINISTRATION;
PRIORITY JOURNAL;
RHEUMATOID ARTHRITIS;
SUBCUTANEOUS DRUG ADMINISTRATION;
ANTIBODIES, MONOCLONAL;
ANTIRHEUMATIC AGENTS;
ARTHRITIS, RHEUMATOID;
DRUG THERAPY, COMBINATION;
HUMANS;
IMMUNOGLOBULIN G;
METHOTREXATE;
RECEPTORS, TUMOR NECROSIS FACTOR;
TUMOR NECROSIS FACTOR-ALPHA;
|
|
EID: 0033611515
PISSN: 00284793
EISSN: None
Source Type: Journal
DOI: 10.1056/NEJM199901283400411 Document Type: Editorial |
|
Times cited : (106)
|
|
References (11)
|
